

Supplemental Table: Detailed information of each study (N = 26) included in the review.

Study	Growth Factor	Animal Model	Surgical Approach	Fusion Level(s)	Study Groups	Spinal Fusion Findings	p-value	Spinal Fusion Assessment Technique	Other Methods of Assessment	Excluded/peri-operative death	Post-operative analgesia/antibiotic	Post-operative follow-up
Zheng et al., 2017	AB204	Beagle dog	Posterolateral	L1-2, L4-5	A. Osteon II (biphasic calcium phosphate), 2 mL	6.3% (1 of 16)	-	Manual palpation (no motion)	Radiography (AP and Lateral), CT, Histology (H&E)	3/17 (perioperative death; bleeding)	Anti-biotics, IM injection of Biotril, 0.1 mL/kg daily for 3 days after surgery	8 weeks
					B. Osteon II, 2 mL, + rhBMP-2, 50 µg	15% (3 of 20)	-		Volume of newly formed bone was significantly higher in Group C compared to Group A and B (p<0.01)			
					C. Osteon II, 2 mL, + AB204, 50 µg	90% (18 of 20)	<0.01, compared to A or B					
Park et al., 2011	COMP-Ang-1	Sprague-Dawley rat	Posterolateral	L3-5	A. ICBG, 1 mL	38.9% (7 of 18)	-	Manual palpation (at least one side lacked motion)	Radiography (PA), micro-CT, biomechanical testing, histology (H&E), histomorphometry, immunohistochemistry (factor VIII-related antigen), RT-PCR (Runx2, BSP, Osteopontin, Type I collagen, Osterix, Osteocalcin, Tie-1, VEGF, Flt-1, Factor VIII, Egr-1)	2/20 (perioperative death)	Analgesics / butorphanol, 0.1 mg/kg body weight	6 weeks
					B. ICBG, 1 mL, + Bovine serum albumin-impregnated absorbable collagen sponge, 100 µg	42.1% (8 of 19)	-		1/20 (perioperative death)			
					C. ICBG, 1 mL, + COMP-Ang-1-impregnated absorbable collagen sponge, 100 µg	89.5% (17 of 19)	<0.01 compared to A or B		1/20 (perioperative death)			

									<p>($p < 0.001$). The mechanical strength was significantly greater in Group C compared to Groups A and B ($p < 0.01$).</p> <p>Immunostaining of endothelial cells for factor VIII revealed higher levels of vascularity in the fusion site in Group C compared to Groups A and B ($p < 0.01$).</p> <p>Runt-related transcription factor 2 and its target genes were significantly up-regulated in Group C compared to Group B ($p < 0.05$).</p>			
Babat et al., 2005	Calcitonin	New Zealand White rabbit	Posterolateral	L5-L6	<p>A. ICBG, 3 mL</p> <p>B. ICBG, 3 mL + pamidronate, 1.2 mg subcutaneously three times/week for 4 weeks preoperatively, then 0.6 mg/day via mini-osmotic pump for 4 weeks postoperatively</p> <p>C. ICBG, 3 mL + calcitonin, 14 IU/day via mini-osmotic pump for 4 weeks postoperatively only.</p>	<p>56% (10 of 18)</p> <p>37% (7 of 19)</p> <p>68% (13 of 19)</p>	No significant differences	Manual palpation (no motion)	<p>Biomechanical testing</p> <p>Group B had significantly less peak load compared to Groups A and C ($p < 0.01$) and were less stiff than Group A ($p < 0.01$) and Group C ($p < 0.05$).</p>	<p>4/60 (1 perioperative death; 1 euthanasia for hind-limb palsy; 1 infection; 1 incorrect fusion level)</p>	<p>Buprenorphine 0.08 mg subcutaneously immediately after surgery. Each animal then received additional buprenorphine 0.08 mg in 12-h intervals,</p>	5 weeks

											as needed	
Liu et al., 2012	Calcitonin	New Zealand White rabbit	Posterolateral	L4-5, L6-7 (for L6-L7, steel wire was used to bind the spinous processes ; for L4-L5, no wire fixation was performed)	A. L4-L5: ICBG, 2.5 mL	75% (3/4)	No significant differences	Radiography (AP)	Histology (H&E), histomorphometry, RT-PCR (BMP-2, Col I, VEGF, IGF-1) Starting at week 2, mRNA levels of Col I, BMP-2, IGF-I, and VEGF were higher in the groups of grafts with calcitonin (B and D) compared to the groups without (A and C) (p < 0.05 for each)	N/A	Antibiotics, Penicillin-G; 40,000 U	1, 2, 4, 8 weeks (data included for 8 weeks)
				B. L4-L5: ICBG, 2.5 mL, + calcitonin, 1 IU/kg/day postoperatively until sacrifice	100% (4/4)							
				C. L6-L7: ICBG, 2.5 mL + steel wire fixation of the L6-7 spinal processes	75% (3/4)							
				D. L6-L7: ICBG, 2.5 mL + steel wire fixation of the L6-7 spinal processes + calcitonin, 1 IU/kg/day postoperatively until sacrifice	100% (4/4)							
Liu et al., 2015	Calcitonin	Sprague-Dawley rat (normal and ovariectomized four weeks before intervention)	Posterolateral	L4-5 (including wire fixation of spinous processes)	A. Sham surgery (not ovariectomized); after four weeks, NO L4-L5 fusion, followed by subcutaneous injection of saline vehicle every 2 days until sacrifice (12 weeks)	Fusion rates not directly given. Fusion outcomes via Radiography: Given scale of 0, no bone; 1, poor new bone formation; 2, moderate new bone formation and definite pseudarthrosis; 3, moderate new bone formation and possible pseudarthrosis; 4, good new bone formation and probable fusion; 5, definite fusion Group C average (n=10): 3.00 ± 0.92 Group D average (n=10): 2.15 ± 0.88		Radiography	Manual palpation, dual energy X-ray absorptiometry (bone mineral density), micro-CT, histology (van Gieson), histomorphometry, and immunohistochemistry (Col I, Col II, aggrecan, MMP-13, ADAMTS-4) Significantly higher Bone Mineral Density observed in Group B v. Group A Bone Mineral Density: • Groups B and	NA	NA	12 weeks
				B. Ovariectomized; after four weeks, NO L4-L5 fusion, followed by subcutaneous injection of saline vehicle every 2 days until sacrifice (12 weeks)								
				C. Sham surgery (not ovariectomized); after four weeks, L4-L5 fusion (ICBG),								

					<div>followed by subcutaneous injection of saline vehicle every 2 days until sacrifice (12 weeks)</div> <div>D. Ovariectomized; after four weeks, L4-L5 fusion (ICBG), followed by subcutaneous injection of saline vehicle every 2 days until sacrifice (12 weeks)</div> <div>E. Ovariectomized; after four weeks, L4-L5 fusion (ICBG), followed by subcutaneous injection of salmon calcitonin (16 IU/kg) every 2 days until sacrifice (12 weeks)</div>	<div>Group E average (n=10): 3.20 ± 0.9</div> <div>Group C v. D, p = 0.043</div> <div>Group D v. E, p = 0.013</div>			<div>D (ovariectomized) significantly lower than all others (p<0.05)</div> <div>• Group E (treated with salmon calcitonin) significantly greater than group D (not treated with salmon calcitonin) (p<0.05)</div>			
Rolfing et al., 2012	EPO	New Zealand White rabbit	Posterolateral	L5-6	<div>A. ICBG, 2 g + 0.3 mL saline daily via subcutaneous injection beginning two days preoperatively and continuing for 17 days postoperatively</div> <div>B. ICBG, 2 g + EPO, 250 IU/kg in 0.3 mL saline daily via subcutaneous injection beginning two days preoperatively and continuing for 17 days postoperatively</div>	<div>71% (10 of 14)</div> <div>86% (12 of 14)</div>	<div>-</div> <div>0.65, compared to A</div>	Manual palpation (no motion)	<div>Micro-CT, Radiographs (AP), histomorphometry, immunohistochemistry (alpha-actin)</div> <div>Bone volume of the fusion mass was significantly greater in Group B compared to Group A (p<0.01).</div> <div>Group B increased vasculature and increased hemoglobin levels (p<0.01)</div>	<div>3/20 (2 perioperative deaths; 1 deep infection)</div> <div>3/20 (perioperative deaths)</div>	<div>Prophylactic antibiotics given intravenously (25 mg/kg cerufoxime)</div> <div>For pain relief, 5 ml of lidocaine was injected at the iliac crests. In addition, a fentanyl plaster releasing</div>	2, 4, and 6 weeks (6-week data provided)

											7.5 mg/h for 72 h was attached after surgery.	
Inoue et al., 2017	bFGF	Sprague-Dawley rat	Posterolateral	L4-5	A. Femoral freeze-dried bone allograft (FDBA), 150 mg incubated with phosphate buffered saline	Fusion rates not directly given. Radiography and micro-CT: Mean grafted bone volume was significantly higher in B than in A P<0.05		Radiography, micro-CT,	Histology (hematoxylin-eosin and von Kossa staining).	N/A	NA	2 weeks
					B. FDBA, 150 mg incubated with bFGF, 0.58 nmol				increase in the number of chondrocytes and fibroblasts around the newly formed bone in B compared to A.			
Spiro et al., 2000	GDF-5	Baboon	Posterolateral	L4-5	A. ICBG, 5 cm ³	22% (2 of 9)	Not reported	Radiography/CT	Histology Group C showed the most robust bone formation histologically, with well-organized fusion masses consisting of inner zones with a high volume of trabecular bone and a provisional cortex with well-formed osteons. Overall cellularity and osteoblast numbers were increased in Group C compared to autograft (Group A).	Not reported	NA	20 weeks
					B. Healos® (collagen matrix strips), two strips per side, 5 cm ³ per strip	0% (0 of 9)						
					C. Healos®, two strips per side, 5 cm ³ per strip + rh-GDF-5, 500 micrograms/cm ³ of Healos®	44% (4 of 9)						
					D. Healos®, two strips per side, 5 cm ³ per strip + rh-GDF-5, 1500 micrograms/cm ³ of Healos®	11% (1 of 9)						
Spiro et al., 2001	GDF-5	New Zealand White	Posterolateral	L5-6	ICBG, 1 cm ³ per side	33% (1 of 3)	Not reported	Histology analysis (bilateral)	Radiography (AP), biomechanical	1/11 (premature death)	NA	12 weeks

		rabbit			Hydroxyapatite-mineralized collagen matrix (Matrix)		0% (0/3)		fusion)	testing In the most efficacious group (80% fusion), most samples demonstrated normal trabecular bone structure with thin outer cortical plates and modest amounts of hematopoietic bone marrow.	1/11 (premature death)		
					Matrix + bone marrow, 4.0 +/- 1.6 mL per animal		0% (0 of 4)				0		
					Healos strips, 1.0x3.0x0.5 cm³, + rhGDF-5, 0.1 mg/cm³ of matrix		0% (0/2)				1/11 (premature death)		
					Healos strips, 1.0x3.0x0.5 cm³, + rhGDF-5, 1.0 mg/cm³ of matrix		67% (2/3)				2/11 (premature death)		
					Non-crosslinked 1.0x3.0x0.5 cm³ mineralized collagen strips + rhGDF-5, 0.1 mg/cm³ of collagen		75% (3 of 4)				0		
					Non-crosslinked 1.0x3.0x0.5 cm³ mineralized collagen strips + rhGDF-5, 1.0 mg/cm³ of collagen		80% (4 of 5)				1/11 (premature death)		
					Collagen fiber slurry + rhGDF-5, 0.1 mg/cm³ of collagen; then molded into 1.0x3.0x0.5 cm³ strips		25% (1/4)				0		
					Collagen fiber slurry + rhGDF-5, 1.0 mg/cm³ of collagen; then molded into 1.0x3.0x0.5 cm³ strips		0% (0/3)				1/11 (premature death)		
Jahng et al., 2004	GDF-5	Sheep	Posterolateral (endoscopic) (screws and plate)	L4-5	In each animal, ICBG was placed on one side of spine and Healos + rh-GDF-5 was placed on the	ICBG, 5 cm³	0% (0 of 4) at 2 months; 100% (4 of 4) at 4 months; 100% (4 of 4) at 6 months)	Not reported	Manual palpation (no unilateral motion)	Radiography (PA), CT, and Histology (osteochrome bone stain), histomorphometry At 6 months, the	0/12 sheep	NA	2, 4, 6 months

									endplates, accompanied by capillary ingrowth and resorptive lacunae, without major differences between the two groups.			
									No differences were found in the bone volume/total volume ratio between Groups B-D.			
Kandziora et al., 2002	IGF-1/TGF-beta	Sheep	Anterior, interbody (left anterolateral)	C3-4	A. ICBG (average of 8 mm x 14 mm x 11 mm)	0% (0 of 8)	N/ A	Histology (complete bony fusion)	Radiography (lateral, PA, and flexion-extension), CT, Biomechanical testing, histomorphometry and fluorochrome analysis	2/34 (1 died perioperatively due to anesthetic complications; another was euthanized during week 6 because of a sore mouth); both animals were replaced in the study.	2 g of amoxicillin intravenously (intravenous Augmentan) before surgery.	12 weeks
					B. Titanium cage	0% (0 of 8)						
					C. Cage + PDLLA carrier	0% (0 of 8)						
					D. Cage + PDLLA carrier including rh-IGF-1, 5% w/w, and rh-TGF-beta-1, 1% w/w (~150 microgram IGF-1 and 30 microgram TGF-beta-1)	12.5% (1 of 8)						
									No significant differences between Groups A-C were found regarding bone mineral content or bony callus volume.		Postoperatively, the sheep received two doses of metamilzol-natrium 0.5 g per day intramuscularly for 5 days.	
									Bone mineral density (BMD) was significantly greater in Groups C and D compared to Groups A and B (p<0.05). There was no significant			

									difference in BMD between Groups C and D. Bony callus volume of Group 4 was significantly higher than in any other group (p<0.05).			
Kandziora et al., 2003	IGF-1/TGF-beta	Sheep	Anterolateral, interbody (left anterolateral approach)	C3-4	A. Titanium cage coated with PDLLA carrier (Cage) B. Cage + IGF-1 (2.5% w/w = 75 micrograms) + TGF-beta-1 (0.5% w/w = 15 micrograms) C. Cage + IGF-1 (5.0% w/w = 150 micrograms) + TGF-beta-1 (1% w/w = 30 micrograms) D. Cage + IGF-1 (10% w/w = 300 micrograms), TGF-beta-1 (2.0% w/w = 60 micrograms)	Fusion rates not directly given. CT & Histomorphometry: Groups C & D demonstrated significantly higher bony callus volumes via CT and an advanced interbody bone matrix formation (bone volume/total volume ratio) via histomorphometrical analysis compared to Groups A and B (p<0.05).	CT and Histomorphometry	Radiography (PA and lateral); biomechanical testing; histomorphological and fluorochrome analysis (safranin-O/lightgreen, safranin-O/van Kossa, Astrablue, and Masson-Goldner) Groups C and D showed extensive callus formation, accompanied by capillary ingrowth and small resorptive lacunae, without major differences between the groups.	0/32	Postoperatively, the sheep received two doses of 0.5 g metamizol-natrium per day for 5 days intramuscularly	12 weeks	
Gu et al., 2016	IGF-1/TGF-beta	Goat	Anterior, interbody (right anterolateral approach)	C3-4	A. ICBG B. Hat-shaped titanium cage (Cage), 14 mm width, 12 mm depth, 8 mm anterior height C. Cage coated with hydroxyapatite D. Cage coated with hydroxyapatite + IGF-1 (5% w/w) and TGF-beta-1 (1% w/w)	0% (0/8) 25% (2/8) 38% (3/8) 63% (5/8)	N/A	Histology (complete bony fusion) Radiography (lateral and AP), biomechanical testing, histology (Masson-Goldner), histomorphology The stiffness of Group D in flexion, extension, and lateral	2/34 (due to anesthesia-related complications during surgery)	All goats received penicillin of 3.2 million-units intramuscularly before surgery Post-	12 weeks	

									<p>bending was significantly greater than that of any other group ($p<0.05$)</p> <p>In Group D, a slightly more advanced bone matrix formation was shown histomorphologically compared to groups 2 and 3.</p>		<p>operatively, all goats received two 800 thousand-unit doses of penicillin intramuscular injections per day for 5 days.</p>	
Koerner et al., 2013	Insulin	Sprague-Dawley rat	Posterolateral	L4-5	A. Sham implant (100% microrecrystallized palmitic acid; 0.3 g) + ICBG (0.3 g)	11% (1 of 9)	<0.05	Manual palpation (no motion)	Growth factor analysis (ELISA), Radiography (PA) and CT	1/20 (perioperative death)	Postoperatively, the surgical site was treated with an antibiotic ointment, and the rats were given a dose of enrofloxacin in antibiotic (10 mg/kg).	8 weeks
					B. Linplant (95% microrecrystallized palmitic acid and 5% bovine insulin; 4U/kg/day insulin release for a minimum of 40 days; 0.3 g) + ICBG, 0.3 g	60% (6 of 10)			<p>At Day 4, there was a significant increase in IGF-I in Group B compared with Group A ($p=.001$). There was no significant increase in TGF beta-1, PDGF-AB or VEGF.</p> <p>Group B had a greater bone volume by micro-CT compared to Group A ($p<0.001$).</p>	0/20		
Lee et al., 2009	NELL-1	Athymic rat	Posterolateral	L4-5	A. PBS lyophilized onto apatite-coated alginate/chitosan particles, 10 mg; resuspended in PBS and mixed with 100 mg of demineralized bone powder and	0% (0 of 5)	NA	Manual palpation (no motion)	<p>Micro-CT, histology (H&E) </p> <p>Micro-CT-based morphometric analysis demonstrated significantly</p>	NA	Postoperatively, the rats were given analgesics (0.05 mg/kg buprenorph	4 weeks

					220 mg hyaluronan to form a moldable putty.				higher bone volume (bone volume/total volume) between the transverse processes in Group B compared to Group A (p = 0.007).		hine) for two days and antibiotics (trimethoprim/sulfamethoxazole) for seven days.	
					B. rh-NELL-1 (10 micrograms) lyophilized onto apatite-coated alginate/chitosan particles, 10 mg; resuspended in PBS and mixed with 100 mg of demineralized bone powder and 220 mg	60% (3 of 5)			Histologically, cortical -like bone bridges connecting the transverse processes were observed in Group B; the appearance was suggestive of endochondral bone formation, without a significant inflammatory reaction in the graft area.			
Li et al., 2010	NELL-1	Athymic rat	Posterolateral	L4-5	A. PBS lyophilized onto β -tricalcium phosphate (β -TCP) microparticles, 50 mg + DBX (demineralized bone matrix mixed with sodium hyaluronate to form a moldable putty), 0.3 mL	25% (2 of 8)	NA	Manual palpation (no motion)	Radiography (PA), micro-CT, Histology (H&E and Masson trichrome), immuno-histochemistry (osteocalcin)	NA	Postoperatively, about 0.05 mg/kg buprenorphine was given twice daily for 2 days, and 48mg/mL trimethoprim/sulfamethoxazole antibiotic was given for 10	4 weeks
					B. NELL-1, 2.5 micrograms, lyophilized onto β -TCP microparticles, 50 mg + DBX, 0.3 mL	75% (6 of 8)			Bone volume in each Nell-1-treated group was significantly greater than that in the Nell-free control group (p<0.001). No significant			
					C. NELL-1, 5 micrograms, lyophilized onto β -	88% (7 of 8)						

					TCP microparticles, 50 mg + DBX, 0.3 mL				<p>difference in bone volume was observed between the two Nell-1-treated groups.</p> <p>Histologically, Nell-1-treated groups (Groups B and C) contained more bone matrix and bone remodeling compared to Group A; Groups B and C also had greater staining for osteocalcin compared to Group A.</p>		days.	
Siu et al., 2011	NELL-1	Rambouillet × Columbian sheep	Ventrolateral retroperitoneal, through the oblique abdominal muscles to the plane ventral to the transverse processes; interbody	L3-4, L5-6	A. Cage (9-mm parallel radiolucent, Vertebral Spacer-CR 889.915; Synthes, Monument, CO) + DBM, 0.4 mL	50% (4/8)		micro-CT	<p>Radiography, micro-CT, histology (H&E, Masson's Trichrome, von Kossa)</p> <p>Bone volume/total volume and bone mineral density were greater in Group D compared to Group A (p<0.01) (no differences were observed between Group C and Group A).</p> <p>Similarly, bone volume/total volume and bone mineral density were greater in</p>	NA	<p>Sheep were perioperatively premedicated with midazolam and ketamine for pain management and cefazolin as an antibiotic</p>	3 months
					B. Cage + heat-inactivated DBM (inDBM), 0.4 mL	50% (2/4)						4 months
					C. Cage + DBM, 0.4mL + NELL-1, 0.3 mg/mL	87.5% (7/8)	0.002, DBM/Nell-1-treated groups compared to DBM/Nell-1-free groups (chi-square)					3 months
					D. Cage + DBM, 0.4mL + NELL-1, 0.6 mg/mL	100% (8/8)						3 months
					E. Cage + inDBM, 0.4mL + NELL-1, 0.3 mg/mL	100% (4/4)	0.01, inDBM/Nell-1-treated					4 months
					F. Cage + inDBM,	100%						4 months

					collagen sponge, 1.25 x 1.25 cm strip per fusion bed) + PBS				greater fractional bone volume to all other groups besides Group F (p<0.01). Histologically, Nell-1-treated groups (Groups B and C) showed increased vascularization and endochondral ossification, whereas Group E showed lipid rich bone formation. Separately, alkaline phosphatase staining and Runx2 expression were significantly increased with Nell-1 (800 ng/mL) and BMP-2 (150 ng/mL) in <i>in vitro</i> assays.			
					E. ACS + BMP-2 (90 microgram)	100% (5/5)						
					F. ICBG (300 microliter)	0% (0/5)						
James et al., 2017	NELL-1	Rhesus macaque	Ventrolateral retroperitoneal approach to L3/L4 and L5/L6 was made through the oblique abdominal muscles to the plane ventral to the L3-L6 transverse processes; 3-hole titanium	L3-4, L5-6	A. Cage (Vertebral Spacer-CR; Synthes) + DBX (morselized Rhesus macaque cortical-cancellous demineralized bone chips with sodium hyaluronate), 0.4 mL + saline-loaded apatite-coated β -tricalcium phosphate (aTCP) microparticles, 25 mg B. Cage + DBX, 0.4 mL	25% (1 of 4) 25% (1 of	NA	CT (50% or greater area of contiguous bridging bone within implant)	Radiography, micro-CT, finite element analysis, histology, histomorphometry, immunohistochemistry (CD31, CD45, Sca-1) Significant increase in bone mineral density and increase in fractional bone	NA	NA	12 weeks

			plate with 2 screws.		+ rhNELL-1-loaded aTCP microparticles, 1.0 mg/ml	4)			volume (bone volume/total volume) and reduction in trabecular spacing in Group C compared to Groups A and B (p<0.01).			
					C. Cage + DBX, 0.4 mL + rhNELL-1-loaded aTCP microparticles, 1.7 mg/ml	100% (4 of 4)			Significant increase in trabecular number in Group C compared to Groups A and B (p<0.05).			
									Via finite element analysis, Group C showed reduced predicted stress among cubic volumes of interest compared to Groups A and B (p<0.05).			
									Via von Kossa histomorphometry quantification, significantly increased percentage of bone area per field in Group C compared to Groups A and B (p<0.01); significant increase in Group B compared to Group A.			
									Immunofluorescence staining			

					alpha-1; ABM = anorganic bovine-derived hydroxyapatite matrix).	PEEK cage	difference found between Groups A and B		materials “ABM/P-15 was as successful as autogenous bone graft”			
Smucker et al., 2008	Peptide B2A	New Zealand White rabbit	Posterolateral	L4-5	A. ICBG, 3 mL	25% (2 of 8)		Manual palpation (bilateral no motion)	Radiography, micro-CT, histology (H&E) Histologically, there was no detection of adverse inflammatory reaction to the B2A/CG regardless of coating concentration (Groups C-E). The newly formed bone in Groups C-E appeared morphologically normally without hyperplasia. Additionally, Group C tended to have more histologic evidence of new bone development across the intertransverse process space compared to Groups A and B.	2/10 animals (“complications arising from surgery”)	NA	6 weeks
					B. 1:1 ICBG: Ceramic Granules (20% hydroxyapatite and 80% tricalcium phosphate; CG), 3 mL	22% (2 of 9)						
					C. 1:1 ICBG:CG (coated with 50 µg B2A/mL), 3 mL total	56% (5 of 9)				1/10 animals (“complications arising from surgery”)		
					D. 1:1 ICBG:CG (coated with 100 µg B2A/mL), 3 mL total	78% (7 of 9)	0.029 compared to A; 0.017 compared to B			1/10 animals (“complications arising from surgery”)		
					E. 1:1 ICBG:CG (coated with 300 µg B2A/mL), 3 mL total	40% (4 of 10)						
Cunningham et al., 2009	Peptide B2A	Crossbred Suffolk sheep	Anterolateral (retroperitoneal) (screw and rod; PEEK cage)	L2-3, L4-5	A. PEEK cage (interbody), 11 mm x 11 mm x 24 mm with 1:1 ICBG: Ceramic Granules (20% hydroxyapatite, 80%	63% (5 of 8)	No significant difference between	CT (“contiguous bone from endplate to endplate”)	CT, Histology, histomorphometry, biomechanical testing Histologically, all	2/20 animals died perioperatively (secondary	Pre-operatively, 0.1 mg/kg butorphanol and 1 g	4 months

					tricalcium phosphate; CG), ~4 mL total B. Interbody with 1:1 ICBG:CG coated with 50 µg B2A/mL; ~4 mL total C. Interbody with 1:1 ICBG:CG coated with 100 µg B2A/mL; ~4 mL total D. Interbody with 1:1 ICBG:CG coated with 300 µg B2A/mL; ~4 mL total E. Interbody with 1:1 ICBG:CG coated with 600 µg B2A/mL; ~4 mL total	88% (7 of 8) 88% (7 of 8) 88% (7 of 8) 75% (6 of 8)	any of the groups		concentrations of B2A (Groups B-E) were characterized as undergoing a normal healing process, without evidence of an inflammatory response or any other significant histopathological change. Group A similarly had good to excellent osseointegration. In biomechanical testing, no differences were observed between any of the groups.	y to pulmonary complications caused by the surgical procedure)	cefazolin sodium Post-operatively, Buprenorphine (0.01–0.1 mg/kg twice a day, intramuscularly) and Ketofen (2.2 mg/kg once a day, subcutaneously) for at least 3 days. All sheep received Cefazolin (1 g twice a day, intramuscularly for 3 days) and then a long-acting penicillin (1 ml = 150,000 U penicillin G-benzathine and 150,000 U penicillin G-procaine)	
--	--	--	--	--	---	--	-------------------	--	--	---	---	--

											for a period of 7 days (4 ml every other day).	
Sintuu et al., 2011	SPP24	Male Lewis rat	Posterolateral	L3-4	A. Collagen sponge, 10 mm x 5 mm x 5 mm	0%	Truncated spp18 (all concentrations grouped together) and full-length spp24 (all concentrations grouped together) were shown to significantly inhibit rh-BMP-2-induced bone formation (p<0.001), as assessed via manual palpation. Full-length spp24 showed a greater inhibitory impact compared to the truncated	Manual palpation	Radiography (AP and lateral), micro-CT, histology (H&E) “when rhBMP-2 was implanted in combination with TR-spp18 or FL-spp24, only single-level fusion or no fusion was observed.” Samples that received either absorbable collagen sponge alone or 1 microgram of rhBMP-2 showed little new bone growth between the transverse processes. The surface of the transverse processes of L4 and L5 receiving 1 microgram of rhBMP-2 was irregular and exhibited features of immature, woven bone. All animals implanted with 10 micrograms of rhBMP-2		NA	8 weeks
					B. Collagen sponge, 10 mm x 5 mm x 5 mm + rhBMP-2, 10 micrograms	100%						
					C. Collagen sponge, 10 mm x 5 mm x 5 mm + rhBMP-2, 1 microgram + SPP24, 0.1 mg	0%						
					D. Collagen sponge + rhBMP-2, 1 microgram + SPP24, 0.5 mg	0%						
					E. Collagen sponge + rhBMP-2, 1 microgram + SPP24, 1 mg	0%						
					F. Collagen sponge + rhBMP-2, 1 microgram + SPP24, 2.5 mg	0%						
					G. Collagen sponge + rhBMP-2, 1 microgram + SPP18 (truncated form), 0.1 mg	0%						
					H. Collagen sponge + rhBMP-2, 1 microgram + SPP18, 0.5 mg	0%				1 (of unknown) (perioperative death); supplemental table online cannot be accessed		
					I. Collagen sponge + rhBMP-2, 1 microgram + SPP18,	0%						

					1 mg		spp18 form		contained bone masses so large that the interface between the transverse processes was indistinguishable. The new bone has features characteristic of endochondral ossification. Specimens receiving 1 microgram of rhBMP-2 and TR-spp18 did not exhibit any new bone formation. Specimens receiving 10 micrograms of rhBMP-2 and TR-spp18 showed some areas of normal remodeling and a smaller area of new bone formation compared to rhBMP-2 implantation alone. Specimens receiving either 1 or 10 micrograms of rhBMP-2 and FL-spp24 exhibited healthy, viable bone, suggesting that FL-spp24 is not toxic to existing bone and only inhibits new bone			
					J. Collagen sponge + rhBMP-2, 1 microgram + SPP18, 2.5 mg	0%						
					K. Collagen sponge + rhBMP-2, 10 micrograms + SPP24, 0.1 mg	0%						
					L. Collagen sponge + rhBMP-2, 10 micrograms + SPP24, 0.5 mg	0%						
					M. Collagen sponge + rhBMP-2, 10 micrograms + SPP24, 1 mg	0%						
					N. Collagen sponge + rhBMP-2, 10 micrograms + SPP24, 2.5 mg	0%						
					O. Collagen sponge + rhBMP-2, 10 micrograms + SPP18, 0.1 mg	0%						
					P. Collagen sponge + rhBMP-2, 10 micrograms + SPP18, 0.5 mg	0%						
					Q. Collagen sponge + rhBMP-2, 10 micrograms + SPP18, 1 mg	0%						
					R. Collagen sponge + rhBMP-2, 10 micrograms + SPP18, 2.5 mg	0%						

									formation mediated by rhBMP-2.			
--	--	--	--	--	--	--	--	--	--------------------------------------	--	--	--